Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

CAPSID
  NCT04433910		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
53/52 inconclusive -15% 52%
CP-COVID-19
  NCT04332835		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
49/51 inconclusive 198%
O’Donnell
  NCT04359810		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive -48% 18%
Pouladzadeh
  IRCT20200310046736N1		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
31/31 suggested -63% 568%
RECOVER
  EudCT 2020-001632-10		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallylow
43/47 inconclusive 8%
REMAP-CAP (plasma)
  NCT02735707		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallylow
1095/916 safety concern -4%
Sekine (PLACOVID)
  NCT04547660		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
80/80 inconclusive 34% -5%
AlQahtani
  NCT04356534		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -47%
Li
  ChiCTR2000029757		 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive -37% 36%
PlasmAr
  NCT04344535		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
Rasheed RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
21/28 inconclusive -79%
7 studies excluded by filtering options (2 RCT / 5 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons